Delivery Order SPE2DB22D2005-SPE2DB25FJSN6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a ceiling value of $4,698.53. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive procurement. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 12, 2025. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a $17,575.18 delivery order to AmerisourceBergen Drug Corp for the supply of Janumet XR 100-1,000 mg tablets (90-count units) under a firm fixed-price contract. The award, issued on September 17, 2025, with an ultimate completion date of September 18, 2025, was made through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, delivered the pharmaceutical product to its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count packages) valued at $3,508.43. This contract utilizes a firm fixed-price structure with an ultimate completion date of September 26, 2025, and was awarded on a competitive basis without any set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180 count) with a ceiling value of $10,520.81. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count) with a ceiling value of $1,746.19. This firm fixed price delivery order, which is not set-aside and represents a competitively awarded contract, is scheduled for completion by July 25, 2025. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a contract ceiling value of $5,550.17. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 17, 2025. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $1,974.21 firm fixed price delivery order to AmerisourceBergen Drug Corp for JANUMET XR 50-1,000 mg tablets (60-count) on September 26, 2025, with completion scheduled for September 29, 2025. The contract, which carries no set-aside designation, was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) under a firm fixed-price arrangement. The $9,811.62 delivery order, which represents a non-set-aside competitive award, is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order through its established...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a ceiling value of $19,423.78. This firm fixed-price delivery order represents a non-set-aside, competitively awarded transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX. The ultimate completion date for this delivery order is August 5,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Janumet XR 50-1,000 mg tablets in a quantity of 180 units. This delivery order, valued at approximately $39,906, represents a firm fixed-price contract with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJSN6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Janumet XR 50-1,000 mg tablets (60-count units) with a ceiling value of $19,258.50. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 26, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026 that enables global pharmaceutical support across multiple therapeutic domains. The company's federal contract portfolio demonstrates consistent capabilities in competitively awarded pharmaceutical supply, with this order contributing to the DLA's medical supply chain requirements for diabetes management medications. AmerisourceBergen Drug Corp's comprehensive contract history with the DLA reflects its established ability to deliver brand-name and generic pharmaceutical products meeting federal procurement standards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.3k | 8/25/25 |